Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.73 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.73 |
| ▸ | MMP3 | P08254 | 2/20 | 0.73 |
| ▸ | MMP13 | P45452 | 2/20 | 0.73 |
| ▸ | GFER | P55789 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6884778 | 0.93 | PTPN1 (0.74) | PTPN1AKR1B1MMP3MMP13GFER | |
| SCHEMBL6884783 | 0.93 | PTPN1 (0.74) | PTPN1AKR1B1MMP3MMP13GFER | |
| SCHEMBL7143955 | 0.93 | AKR1B1 (0.71) | PTPN1AKR1B1MMP3MMP13GFER | |
| SCHEMBL7143950 | 0.93 | AKR1B1 (0.71) | PTPN1AKR1B1MMP3MMP13GFER | |
| SCHEMBL7398219 | 0.92 | MEN1 (0.65) | PTPN1AKR1B1MMP3MMP13GFER | |
| SCHEMBL7399985 | 0.92 | POLB (0.78) | PTPN1AKR1B1MMP3MMP13GFER | |
| SCHEMBL7144808 | 0.92 | MEN1 (0.65) | PTPN1AKR1B1MMP3MMP13GFER | |
| SCHEMBL7144366 | 0.92 | MEN1 (0.65) | PTPN1AKR1B1MMP3MMP13GFER | |
| SCHEMBL7144369 | 0.92 | MEN1 (0.65) | PTPN1AKR1B1MMP3MMP13GFER | |
| SCHEMBL7145580 | 0.92 | POLB (0.78) | PTPN1AKR1B1MMP3MMP13GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506755-B2 | 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis | HOFFMANN-LA ROCHE INC. | 2003-01-14 | — | — | US | disclosed |
| US-20020037901-A1 | Thiazolidinecarboxyl acids | HOFFMANN-LA ROCHE INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1189894-A1 | THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001057006-A1 | THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037901-A1 | Thiazolidinecarboxyl acids | TPMT, NAT1, THRA | PTPN1 312/4885AKR1B1 281/4885MMP3 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.